卵巢癌的基因相關治療

Gene-related therapy in ovarian cancer

晚期卵巢癌的治療在過去半世紀，進步龜速，令人氣餒。標靶分子治療（基因相關治療）興起，攻擊腫瘤而不傷及正常組織，毒性又低，對傳統化療和放療都有加分的效果。本文根據臨床研究成功案例，包含單株抗體治療，蛋白抑制劑，免疫檢查站抑制劑，基因藍子療法等做一個簡要的介紹，為目前晚期卵巢癌的治療做一個分析，為未來個人化的治療做一個策劃。

In most developed countries, epithelial ovarian cancer bears the notorious name of number one killer in female genital cancers, hence it provokes development of novel strategies in combination therapies. The gene-related therapy or molecularly targeted therapy offers an optimal choice due to its being highly specific in targeting and the least toxic to normal tissues. Furthermore, it provides an additive effect to chemotherapy and radiotherapy. In this review article, we will discuss concepts and roles of some newly developed generelated therapies based upon evidence of successes in clinical trials, including antibody therapy, protease inhibitory therapy, PARP-1/BRCA1/2 therapy, immune checkpoint therapy, basket trial / therapy and genome-based trials. Through individual analysis of each patient's tissue or other samples, the so-called personalized therapy may become the mainstay of future cancer therapies.